Edwards Lifesciences Corporation $EW Shares Sold by Resona Asset Management Co. Ltd.

Resona Asset Management Co. Ltd. cut its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 5.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 192,105 shares of the medical research company’s stock after selling 10,294 shares during the period. Resona Asset Management Co. Ltd.’s holdings in Edwards Lifesciences were worth $14,922,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Rosenberg Matthew Hamilton acquired a new stake in shares of Edwards Lifesciences in the second quarter valued at $28,000. True Wealth Design LLC raised its position in shares of Edwards Lifesciences by 251.5% during the 3rd quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock worth $28,000 after acquiring an additional 259 shares in the last quarter. NewSquare Capital LLC raised its holdings in Edwards Lifesciences by 57.8% during the second quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock worth $29,000 after purchasing an additional 134 shares in the last quarter. Rakuten Securities Inc. raised its stake in Edwards Lifesciences by 413.7% during the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock worth $29,000 after acquiring an additional 302 shares in the last quarter. Finally, Steigerwald Gordon & Koch Inc. purchased a new stake in shares of Edwards Lifesciences in the 3rd quarter valued at about $30,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

EW has been the subject of a number of research reports. Citigroup reaffirmed a “buy” rating and issued a $101.00 target price (up from $96.00) on shares of Edwards Lifesciences in a report on Thursday, December 11th. Evercore ISI restated an “outperform” rating and set a $94.00 target price on shares of Edwards Lifesciences in a research report on Monday, January 5th. Truist Financial set a $92.00 price target on Edwards Lifesciences and gave the stock a “hold” rating in a research note on Friday, December 5th. Robert W. Baird set a $90.00 price objective on shares of Edwards Lifesciences in a research note on Monday, January 12th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Wednesday. Three analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $96.82.

Insider Activity

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 11,386 shares of the business’s stock in a transaction on Friday, December 12th. The shares were sold at an average price of $83.76, for a total value of $953,691.36. Following the transaction, the vice president owned 38,970 shares in the company, valued at $3,264,127.20. The trade was a 22.61% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Daniel J. Lippis sold 1,020 shares of the firm’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $82.55, for a total value of $84,201.00. Following the sale, the vice president owned 22,002 shares of the company’s stock, valued at $1,816,265.10. This represents a 4.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 57,824 shares of company stock worth $4,863,323. 0.34% of the stock is currently owned by company insiders.

Edwards Lifesciences Price Performance

Shares of NYSE EW opened at $83.70 on Monday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.00 and a quick ratio of 3.29. Edwards Lifesciences Corporation has a 1-year low of $65.94 and a 1-year high of $87.89. The company has a market capitalization of $48.57 billion, a price-to-earnings ratio of 36.08, a PEG ratio of 3.19 and a beta of 0.95. The business has a 50-day moving average of $84.99 and a 200-day moving average of $80.85.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.59 by $0.08. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The firm had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same period in the previous year, the company posted $0.67 EPS. Edwards Lifesciences’s revenue for the quarter was up 14.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. On average, equities analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.